article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Food and Drug Administration (FDA) approved Epidiolex, a drug containing Cannabidiol (CBD). The FDA’s approval of the drug is just one step toward getting Epidiolex on the market and available to doctors to prescribe as a treatment option. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court.

DEA 113
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

Though it doesn’t get users high like THC-dominant products, CBD is all the rage these days due to its medical benefits and gray-area legality. On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances.

DEA 51
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CBD: Everything You Need to Know

CannaMD

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. So sit back, relax – and if you can’t relax, grab some CBD! What is CBD? Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol.

CBD 99
article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66
article thumbnail

DEA-Licensed Biopharmaceutical Research Company to Partner with CURE Pharmaceutical to Produce Federally-Compliant Cannabis-Based Medical Products

Cannabis Law Report

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. The partnership will initiate the development of CBD and THC oral thin films for CURE’s clinical studies targeted at advancing veteran health.

DEA 59
article thumbnail

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

Cannabis Law Report

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

article thumbnail

Seyfarth on CBD – February 2020 Update

The Blunt Truth

CBD continues to flourish in the markets despite lack of federal regulations, and we’ve identified some significant events that indicate there’s no sign it’s stopping. Topical CBD Pain-Relief Receives FDA Product Listing Certification. This certification is the first of its kind for a topical OTC drug containing CBD.

CBD 99